Ideaya Biosciences Inc

NASDAQ:IDYA  
14.94
+0.83 (+5.88%)
Earnings Announcements

Ideaya Reports Positive Interim Phase 2 Clinical Results For Darovasertib And Crizotinib Synthetic Lethal Combination In Metastatic Uveal Melanoma

Published: 09/11/2022 21:10 GMT
Ideaya Biosciences Inc (IDYA) - Ideaya Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma.
Ideaya Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma.
Targeting to Initiate Potential Registrational Trial for Daro + Crizo in First-line Mum in Q1 2023.
Targeting to Initiate Company-sponsored Trial for Daro Monotherapy in (neo)adjuvant Um in Q4 2022.
Revenue is expected to be $6.64 Million
Adjusted EPS is expected to be -$0.61

Next Quarter Revenue Guidance is expected to be $6.64 Million
Next Quarter EPS Guidance is expected to be -$0.68

More details on our Analysts Page.